Bothell-based biotech, Curevo Vaccine, has a new home in the Seattle suburb.
The shingles vaccine maker is leasing more than 13,600 square feet of office space at Plaza at North Creek in Bothell, about 4 miles south of its previous location in the city.
The company, founded in 2017, is developing a vaccine called CRV-101 in phase 2 trials with 678 subjects for its prevention of shingles in older adults. It’s also investigating the drug’s potential to protect immunocompromised children from chickenpox.
The company last year raised $86 million, which its CEO, George Simeon, said “is a meaningful demonstration of the confidence our investors have in the CRV-101 program.”